Received: 5 November 2018
Accepted: 31 January 2019
First Online: 12 March 2019
Ethics approval and consent to participate
: For the SA501 patient derived xenograft, the anonymized human tumor tissue for xenografting was collected with informed patient consent according to procedures approved by the Ethics Committee at the University of British Columbia, under protocols H06-00289 BCCA-TTR-BREAST and H11-01887 Neoadjuvant Xenograft Study.For the OV2295 Tumor and ascites samples were collected with informed consent from the Centre hospitalier de l’Université de Montréal (CHUM), Hôpital Notre-Dame, in the Department of Gynecologic Oncology. The study was approved by the Comité dé’thique de la recherché du CHUM, the institutional ethics committee.All experimental methods comply with the Helsinki declaration.
: All patients provided written consent for publication as per previous studies [CitationRef removed,CitationRef removed].
: SPS and SA are founders, shareholders, and consultants of Contextual Genomics Inc. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.